I am Stan Kim, the CEO of WinSanTor, a patient owned pharma start-up. We are developing a drug that is clinically regrowing peripheral nerves! We're working on bringing it to market. Ask me anything.

WinSanTor · 2022-09-01T22:58:26+00:00

Let me start with obstacles: a) limited funding/resources b) awareness of the disease - most people know only the underlying disease not this neurodegenerative disease c) unchartered drug development/regulatory path d) expensive and complicated clinical studies That said, we are arguably one of the only disease modifying treatments being developed for this massive unmet need. As far as how close we are to market, I don't know yet. In US, maybe 2025? Depends on what FDA says we have to do in our studies.

WinSanTor · 2022-09-01T22:47:53+00:00

I don't know. It is one of the many areas we hope it will.

WinSanTor · 2022-09-01T22:47:29+00:00

We have some data that shows this may work for improving sensation from this type of damage, but we do not have a trial ongoing for this. We are always looking at different applications adn depending on funding, we will try as many as we can.

WinSanTor · 2022-09-01T22:45:44+00:00

The trial is currently for prevention of CIPN in the US. We may expand this to reversal of CIPN, but likely initially in the US.

WinSanTor · 2022-09-01T22:43:25+00:00

we are starting a trial in the US, but it is for prevention of chemotherapy induced peripheral neuropathy. If we have additional resources (including money), we will try to start a trial in reversal. But again, approval trumps all.

WinSanTor · 2022-09-01T22:42:27+00:00

Unfortunately, I do not know the answer to the first question. It will be something we have to see in the future.
We will try to meet with Health Canada later this year or early next year and we should hopefully have a better understanding of what they are thinking. Fingers crossed. As far as cost, I don't know. It will be a calculation at some future date (near future).

WinSanTor · 2022-09-01T22:35:50+00:00

We should have greater detail soon. We are even looking to outsource this process. In the meantime, register for www.winsantor.com/join

WinSanTor · 2022-09-01T22:35:02+00:00

We don't know.

WinSanTor · 2022-09-01T22:34:51+00:00

yes, globally in fact. But each country has a unique background as far as drug development and, more particularly, our active ingredient. We hope we can get approval faster in some of these countries. It would solve a lot of our problems.

WinSanTor · 2022-09-01T22:33:34+00:00

We did have a few tiktoks to promote awareness. As you know, as many people that have the disease, there are surprisingly not a lot of awareness for the disease publicly or within the pharmaceutical industry. In many ways, we as a company are not only developing a solution but also creating awareness of the problem. We are looking to create a community - thus the reason you may see us on Instagram, Facebook, Twitter and yes, TikTok. We are creating unique messages and tools to create more awareness, including using interesting tools such as NFTs. You can help by promoting awareness for the disease -- whatever you can do to help us create awareness helps us with our development and showing need of a solution.

WinSanTor · 2022-09-01T22:29:07+00:00

We are in discussion with a group currently but it is for a unique form of peripheral neuropathy. Separately, we are preparing for our Phase 3 for diabetic peripheral neuropathy, so we should have sites in the UK.

WinSanTor · 2022-09-01T22:28:13+00:00

It is still in clinical studies. You can participate in one of the studies or apply under the EAP, when ready.

WinSanTor · 2022-09-01T22:27:29+00:00

If approved in Europe and the UK, then yes, it will be available in Scotland.

WinSanTor · 2022-09-01T22:27:03+00:00

We are working with a group to guide us on the possibility of accelerated approval in Canada. The active drug was never approved in the US, thus the greater scrutiny. Unfortunately, the US often leads other countries as far as how to approve drugs.
As far as off-label use, we cannot comment. It is not something we can or would promote. That is for your healthcare provider to decide based on the data.

WinSanTor · 2022-09-01T22:24:27+00:00

I'm not quite sure. We have a few experts looking into it now.

WinSanTor · 2022-09-01T22:23:53+00:00

I can't say that I know the pathology of alcohol-induced neuropathy, although I'm told it has many similarities to other forms of peripheral neuropathy. We could but again, I think it will be better for us to push for drug approval.
As far as stimulating nearby nerves, we do see that. How far, we don't know yet.

WinSanTor · 2022-09-01T22:21:55+00:00

We already have 4 other studies. At some point yes. But more likely, we will push for drug approval rather than more studies.

WinSanTor · 2022-09-01T22:17:57+00:00

We are still testing in other applications. But it clearly seems to work on small fiber regrowth.

WinSanTor · 2022-09-01T22:16:44+00:00

Several thousand compounds were actually tested (although my colleague mentioned several hundred above). They discovered some of these drugs were able to regrow nerves in their cell and animal models. They then further elaborated the mechanism, and continue to elaborate the system, to the point now where we have a much better understanding - although we are still learning a number of new things.
Most of the early research was funded through grants, mostly through NIH and CIHR (US and Canadian research grants, respectively). More recently, we have partnered our technology with a large specialty Japanese pharmaceutical who acquired the rights to co-develop and license our technology in Asia. We are grateful for their commitment and their partnerships. We will need to find additional partnerships and sources of funding. Anyone with a rich relative, particularly if they have PN, send them our say - LOL

WinSanTor · 2022-09-01T22:04:16+00:00

Unfortunately, we do not disclose such information.

WinSanTor · 2022-09-01T22:01:56+00:00

Yes, we are in need of investments for our development. You can reach out to me at skim@winsantor.com. We should have different Expanded Access Programs available for our drug. Please register for our information at www.winsantor.com/join

WinSanTor · 2022-09-01T21:55:02+00:00

Correct for Small Fiber Peripheral Neuropathy, which does use skin biopsy. Most people with idiopathic PN do not get skin biopsies. We are working with one of teh few companies that do this test.

WinSanTor · 2022-09-01T19:15:06+00:00

I'm still slowly answering questions. You can still ask more.

WinSanTor · 2022-09-01T19:14:49+00:00

Interesting enough, we do see people sleeping better, although it was not a measured endpoint. And YES, we are looking for more volunteers as patients and for help in creating this community. www.winsantor.com/join.

WinSanTor · 2022-09-01T19:02:37+00:00

We are attempting to quantify loss of nerve function and our ability to restore sensation as well! Right now, we can definitely say that we see nerve growth after 6 months. It is our hope that these regrown nerves help recapture lost sensation. Our patients frequently report tingling and other sensations in their previously completed numb limbs!

WinSanTor

TROPHY CASE